Atreca initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of Atreca with a Buy rating and $10 price target. Atreca has developed a unique platform to discover and develop novel antibody-based immuno-therapeutics for solid tumors, Butler tells investors in a research note. The anlayst says the company’s lead product candidate ATRC-101, a monoclonal antibody, is in Phase 1 clinical development in a variety of solid cancers targeting an intracellular ribonucleoprotein complex in tumors.